Piramal Snaps Up Peptide API Specialist Hemmo
Bolsters CDMO Business In Deal Worth More Than $100m
Executive Summary
Piramal has announced a $106m deal to take full ownership of peptide API specialist Hemmo Pharmaceuticals, expanding its CDMO capabilities.
You may also be interested in...
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Action Needed To Prevent Post-Brexit Catastrophe In Northern Ireland
Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.